Thank you, Madam Chair.
I truly agree with what Mr. Gagnon and Ms. Lambert said about addressing safety issues before drugs are made available on the market.
That's one of the questions we really have to deal with today. The government seems to be fixated on this notion of progressive licensing. Some believe that a part of it's being designed to get drugs on the market faster and thereby minimize the safety precautions at the front end. And that's a big part of what we should be looking at and what the government is out there doing anyway.
We need to get some comments from all of you on this whole new approach to licensing and its impact in terms of drug safety.
Jeff, do you want to start?